경피 흡수성 피부 패치 시장 예측(-2030년) : 성분별, 용도별, 유통 채널 및 지역별 세계 분석

According to Stratistics MRC, the Global Transdermal Skin Patches Market is accounted for $8.2 billion in 2023 and is expected to reach $12.8 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Transdermal skin patches are medical devices designed to deliver medication through the skin and into the bloodstream. Comprising layers including an adhesive, drug reservoir and a controlling membrane, these patches offer controlled, continuous drug release. They adhere to the skin, allowing drugs to be absorbed directly into circulation, bypassing the digestive system. They provide a convenient, non-invasive delivery method for various medications, maintaining steady therapeutic levels over time.

According to the GLOBOCAN 2020 report, 195,499 cancer cases were reported in Mexico in 2020, with breast and prostate cancers being the most common among the population.

Market Dynamics:

Driver:

Increasing advantages over the oral and ingesting medications

The rising preference for transdermal skin patches is fueled by their distinct advantages over oral medication. These patches offer non-invasive drug delivery, bypassing the digestive system and reducing gastrointestinal side effects. They ensure a steady, controlled release of medication, maintain consistent therapeutic levels and enhance patient compliance. With fewer dosing frequencies and simplified application, they provide convenience, especially for long-term therapies. Additionally, transdermal patches mitigate issues related to drug degradation in the digestive tract, improving bioavailability and offering a promising alternative to traditional oral medications.

Restraint:

Lack of awareness and elevated product costs

The limited awareness surrounding transdermal skin patches and their higher product costs pose significant restraints. Insufficient knowledge among consumers and healthcare professionals about their benefits and applications may limit their adoption. Moreover, elevated production expenses involved in formulating and manufacturing these patches contribute to higher market prices, impacting accessibility for some patients. These combined factors hinder widespread acceptance and affordability, impeding the potential utilization of this effective drug delivery system for various medical conditions.

Opportunity:

Growing need for prescription transdermal patches

The increasing demand for prescription transdermal patches presents a significant opportunity in the transdermal skin patch market. This surge reflects evolving preferences for non-oral drug delivery methods and a growing emphasis on patient convenience. With a shift toward personalized medicine and targeted therapies, the need for specialized, prescription-based patches is rising. It also fuels research into enhanced patch technologies, expanding treatment options and driving market growth in the transdermal medication sector.

Threat:

Skin's limited capacity to absorb various active substances 

The skin's selective permeability poses a challenge for transdermal patches, as not all substances can effectively penetrate its barriers. This limitation restricts the range of medications suitable for transdermal delivery, hindering the development of certain therapies. Additionally, large molecules, hydrophilic compounds and those with specific chemical properties struggle to traverse the skin barrier effectively, limiting the range of substances suitable for transdermal delivery.

COVID-19 Impact:

The COVID-19 pandemic has significantly influenced the transdermal skin patches market. While demand for certain patches, like those delivering pain relief or hormone therapies, remained steady, disruptions in supply chains and healthcare access impacted production and distribution. Lockdowns also affected patient consultations, potentially hindering new prescriptions and routine check-ups for patch users. However, the pandemic underscored the significance of non-invasive drug delivery methods, potentially driving further innovation and adoption of transdermal patches in the future.

The drug-in-adhesive segment is expected to be the largest during the forecast period

The drug-in-adhesive segment is expected to dominate the market during the forecast period due to its advantages. Drug-in-adhesive patches integrate the drug directly into the adhesive layer, ensuring precise dosing and enhanced skin contact. This design offers convenience, simplicity in application, and consistent drug delivery. Moreover, it minimizes the risk of accidental detachment. With its user-friendly application and reliable drug release profile, the drug-in-adhesive patch is anticipated to remain the preferred choice, fostering its prominence in the market.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is poised for significant growth due to various factors. Hospitals play a pivotal role in patient care and are key distribution points for pharmaceuticals, including transdermal patches. The increasing prevalence of chronic diseases requiring long-term medication, coupled with the rising adoption of transdermal drug delivery systems, is driving demand in hospital pharmacies. Additionally, the convenience of obtaining and administering patches within a hospital setting contributes to the projected substantial growth of the market.

Region with largest share:

North America is anticipated to lead the transdermal skin patches market due to its advanced healthcare infrastructure, high healthcare expenditure and robust focus on technological advancements in drug delivery systems. Additionally, a growing elderly population with chronic conditions, coupled with the prevalence of lifestyle-related diseases, fuels the demand for transdermal patches. Moreover, supportive regulatory frameworks and a strong presence of key market players contribute to North America's anticipated dominance.

Region with highest CAGR:

Asia Pacific is poised for notable growth in the transdermal skin patches market owing to the region's expanding population, rising healthcare awareness and increasing prevalence of chronic diseases. Moreover, improving healthcare infrastructure, a shift towards non-invasive treatments, and the presence of emerging economies fostering healthcare advancements contribute to the projected substantial growth in Asia Pacific. Additionally, supportive government initiatives and a focus on enhancing healthcare accessibility further propel market expansion in this region.

Key players in the market:

Some of the key players in transdermal skin patches market include 4P Therapeutics, AdhexPharma, Aveva Drug Delivery Systems, Bayer AG, Corium, LLC, GlaxoSmithKline (GSK), Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Luye Pharma Group, Mundipharma, Mylan N.V., Nitto Denko Corporation, Novartis, Pfizer Inc., Praj HiPurity Systems Limited, ProSolus Pharmaceuticals, Sorrento Therapeutics Inc, Teva Pharmaceuticals, TheraDep Technologies and Transdermal Delivery Solutions Corporation.

Key Developments:

In April 2023, researchers at MIT University developed a wearable patch that enables painless skin patch delivery. The patch utilizes painless ultrasonic waves to create tiny channels, allowing drugs to pass through the tough outer layer of the skin. This innovative approach holds the potential for delivering treatments for various skin conditions. This patch can also be adapted for delivering muscle relaxants, hormones, and other drugs.

In September 2022, Corium launched its Adlarity (donepezil transdermal system) for prescription use in the US Adlarity, a once-weekly patch, delivers consistent doses of donepezil through the skin. It could treat patients with mild, moderate, or severe dementia of Alzheimer's type.

In April 2022, Luye Pharma Group announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) had accepted the Marketing Authorization Application (MAA) for the company's investigational Rivastigmine Twice Weekly Transdermal Patch that was indicated for treating Alzheimer's disease of mild to moderate symptoms.

Components Covered:

• Reservoir
• Drug-in-Adhesive
• Matrix
• Microneedle
• Other Components

Applications Covered:

• Pain Management
• Cardiovascular Disorders
• Central Nervous System Disorders
• Hormonal Therapy
• Neurological Disorders
• Nicotine Cessation
• Overactive Bladder
• Other Applications

Distribution Channels Covered:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Transdermal Skin Patches Market, By Component

• 5.1 Introduction
• 5.2 Reservoir
• 5.3 Drug-in-Adhesive
  • 5.3.1 Single Layer
  • 5.3.2 Multilayer
• 5.4 Matrix
• 5.5 Microneedle
• 5.6 Other Components

6 Global Transdermal Skin Patches Market, By Application

• 6.1 Introduction
• 6.2 Pain Management
• 6.3 Cardiovascular Disorders
• 6.4 Central Nervous System Disorders
• 6.5 Hormonal Therapy
• 6.6 Neurological Disorders
• 6.7 Nicotine Cessation
• 6.8 Overactive Bladder
• 6.9 Other Applications

7 Global Transdermal Skin Patches Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Online Pharmacies
• 7.4 Retail Pharmacies

8 Global Transdermal Skin Patches Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 4P Therapeutics
• 10.2 AdhexPharma
• 10.3 Aveva Drug Delivery Systems
• 10.4 Bayer AG
• 10.5 Corium, LLC
• 10.6 GlaxoSmithKline (GSK)
• 10.7 Hisamitsu Pharmaceutical Co., Inc.
• 10.8 Johnson & Johnson
• 10.9 Luye Pharma Group
• 10.10 Mundipharma
• 10.11 Mylan N.V.
• 10.12 Nitto Denko Corporation
• 10.13 Novartis
• 10.14 Pfizer Inc.
• 10.15 Praj HiPurity Systems Limited
• 10.16 ProSolus Pharmaceuticals
• 10.17 Sorrento Therapeutics Inc
• 10.18 Teva Pharmaceuticals
• 10.19 TheraDep Technologies
• 10.20 Transdermal Delivery Solutions Corporation